Trial reportDigestive diseases and sciences2010
Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease.
Trial report in Digestive diseases and sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review.Medicine · 2015Pooled it
- A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China.Advances in therapy · 2024Article
- Intravenous Irons: From Basic Science to Clinical Practice.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Disease Patients in the United States, 2010-2014.Inflammatory bowel diseases · 2018Article
- Improving IBD Care: A Personalized Approach to Management.Gastroenterology & hepatology · 2018Article
- Management of Anemia in Patients with Inflammatory Bowel Disease (IBD).Current treatment options in gastroenterology · 2018Review
- Review
- Practical guidance for the management of iron deficiency in patients with inflammatory bowel disease.Therapeutic advances in gastroenterology · 2018Review
- Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders.Clinical and experimental gastroenterology · 2016Article
- Iron deficiency anemia in inflammatory bowel disease.World journal of gastrointestinal pathophysiology · 2015Review
- Management of Iron Deficiency Anemia.Gastroenterology & hepatology · 2015Article
- Anaemia in inflammatory bowel disease.Frontline gastroenterology · 2014Review
- Anemia in inflammatory bowel disease: a neglected issue with relevant effects.World journal of gastroenterology · 2014Review
- Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide.Drugs · 2013Review
- Iron deficiency anemia in patients with inflammatory bowel disease.Clinical and experimental gastroenterology · 2013Article
- Management of iron deficiency anemia in inflammatory bowel disease - a practical approach.Annals of gastroenterology · 2013Review
- Diagnosis and management of iron deficiency anemia in patients with IBD.Nature reviews. Gastroenterology & hepatology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravenous iron has been suggested as a safe and effective treatment of anemia complicating inflammatory bowel disease (IBD). Low molecular weight (LMW) iron dextran has the ability to administer the patient's total iron requirement in a single infusion.
aimsThe aim of this study was to assess the safety and efficacy of the total dose of LMW iron dextran infusion for the treatment of iron deficiency in IBD.
methodsFifty IBD patients (27 female, 35 Crohn's disease, 15 ulcerative colitis) were included in the study. Mean +/- standard deviation (SD) hemoglobin and ferritin levels before the infusion were 9.88 +/- 1.42 g/dl and 13.9 +/- 10.9 ng/ml, respectively. A 25-mg test dose was followed by infusion of the total dose of LMW iron dextran based on the iron deficit. Several clinical and laboratory parameters were measured before and on week 4 after infusion.
resultsFour patients (8%) developed adverse reactions during the test infusion and did not receive the total-dose infusion. Only one patient developed an allergic reaction during the total-dose infusion. In the remaining 45 patients, the mean +/- SD iron dose that was given was 1,075 +/- 269 mg. The mean +/- SD elevation of hematocrit and hemoglobin on week 4 was 4.9 +/- 1.9% and 1.7 +/- 0.8 g/dl, respectively. Hematopoietic response was observed in 23 of 45 patients (51.1%).
conclusionTotal parenteral iron replacement with LMW iron dextran is an easy, safe, and effective alternative method for treating iron deficiency anemia in IBD. Harmless adverse reactions may develop in a minority of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.